

2023 ANUAL MEETING

# BEST OF ASCO®

OFFICIALLY LICENSED

06&07  
JULHO  
2023



HOTEL  
VILA GALÉ  
COIMBRA

6 de julho de 2023

SALA A

8h30-9h10 – SESSÃO DE ABERTURA BEST OF ASCO 2023

9h10-10h25 – **CANCRO DA MAMA PRECOCE**

Moderadores: Luís Costa, Sofia Braga  
Palestrante: Sónia Oliveira

- Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019.
- Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.
- Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer.
- Efficacy and safety results by age in monarche: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).

10h45-11h45 – **SIMPÓSIO\***

11h45-13h00 – **CANCRO GINECOLÓGICO**

Moderadores: Lurdes Batarda, Fátima Vaz  
Palestrante: Mafalda Casa-Nova

- Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
- An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
- Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.
- Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.

2023 ANUAL MEETING

# BEST OF ASCO®

OFFICIALLY LICENSED

06&07  
JULHO  
2023



HOTEL  
VILA GALÉ  
COIMBRA

6 de julho de 2023

SALA A

## 14h00-15h15 — CANCRO DO PULMÃO

Moderadores: Ricardo da Luz, Marcos Pantarotto  
Palestrante: Fernanda Estevinho

- OS survival analysis from the ADURA trial of adjuvant osimertinib in patients with resected EGFR-mut stage 1B-IIIa NSCLC.
- IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (Pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CTG, NCIN, and IFCT trial.
- Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
- Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.

## 15h15-16h15 — SIMPÓSIO\*

## 16h15-17h30 — CANCRO DO PANCREAS E VIAS BILIARES

Moderadores: Hélder Mansinho, António Teira  
Palestrante: Sara Meireles

- Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).
- Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.
- Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).
- Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.



2023 ANUAL MEETING

**BEST OF ASCO**<sup>®</sup>  
OFFICIALLY LICENSED

**06&07  
JULHO  
2023**



HOTEL  
**VILA GALÉ  
COIMBRA**

6 de julho de 2023

SALA A

17h30-18h45 — **IMUNOTERAPIA E BIOLOGIA TUMORAL**

Moderadores: Catarina Portela, Alexandra Araújo

Palestrante: Catarina Abreu

- Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.
- Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).
- Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY -PanTumor02 (DP-02) interim results.
- Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study.

2023 ANUAL MEETING

# BEST OF ASCO<sup>®</sup>

OFFICIALLY LICENSED

06&07  
JULHO  
2023



HOTEL  
VILA GALÉ  
COIMBRA

6 de julho de 2023

SALA B

8h30-9h10 – SESSÃO DE ABERTURA BEST OF ASCO 2023

9h10-10h25 – **CANCRO ESOFAGO-GASTRICO**

Moderadores: Sandra Bento, Tânia Rodrigues  
Palestrante: Jorge Cruz

- ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.
- Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial.
- Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
- KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.

10h45-11h45 – **SIMPÓSIO**

11h45-13h00 – **UROLOGIA NAO-PROSTATA**

Moderadores: Joaquina Maurício, Pedro Madeira  
Palestrante: Sandra Custódio

- Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
- Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
- Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.
- Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).



2023 ANUAL MEETING

# BEST OF ASCO®

OFFICIALLY LICENSED

06&07  
JULHO  
2023



HOTEL  
VILA GALÉ  
COIMBRA

6 de julho de 2023

SALA B

## 14h00-15h15 — CANCRO CABEÇA E PESCOÇO

Moderadores: José Dinis, José Alberto Teixeira

Palestrante: Joana Godinho

- PD-1 blockade with Sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): a multicenter, phase 3, randomized controlled trial (CONTINUUM).
- Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.
- Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.
- Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.

## 15h15-16h15 — SIMPÓSIO

## 16h15-17h30 — PELE

Moderadores: Paula Ferreira, Hugo Nunes

Palestrante: Mariana Inácio

- External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.
- Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
- Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
- Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma (MCC) (CheckMate 358).

2023 ANUAL MEETING

**BEST OF ASCO**<sup>®</sup>  
OFFICIALLY LICENSED

**06&07  
JULHO  
2023**



HOTEL  
**VILA GALÉ  
COIMBRA**

6 de julho de 2023

SALA B

17h30-18h45 — **SURVIVORSHIP**

Moderadores: Teresa Carvalho, Matilde Salgado

Palestrante: Filipe Coutinho

- A multicenter randomized controlled trial (RCT) for the effectiveness of Comprehensive Geriatric Assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study.
- Reduced symptom burden after implementation of an electronic symptom management program.
- Telehealth-based psychological intervention for caregivers of patients with primary malignant brain tumors: A randomized controlled trial.
- Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.



2023 ANUAL MEETING

# BEST OF ASCO®

OFFICIALLY LICENSED

06&07  
JULHO  
2023



HOTEL  
VILA GALÉ  
COIMBRA

7 de julho de 2023

SALA A

8h30-9h10 – SESSÃO DE ABERTURA BEST OF ASCO 2023

9h10-10h25 – **CANCRO DA MAMA AVANÇADO**

Moderadores: Ana Martins, Susana Sousa  
Palestrante: Margarida Brito

- An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.
- Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).
- Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).
- Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.

10h45-11h45 – **SIMPÓSIO\***

11h45-13h00 - **UROLOGIA-PROSTATA**

Moderadores: António Quintela,  
Palestrante: Francisco Branco

- Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.
- Prognostic impact of PSA nadir (n)  $\geq 0.1$  ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.
- TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
- Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status.

2023 ANUAL MEETING

# BEST OF ASCO®

OFFICIALLY LICENSED

06&07  
JULHO  
2023



HOTEL  
VILA GALÉ  
COIMBRA

7 de julho de 2023

SALA B

8h30-9h10 – SESSÃO DE ABERTURA BEST OF ASCO 2023

9h10-10h25— COLON E RETO

Moderadores: Cristina Sarmiento, Anabela Barros

Palestrante: Dânia Marques

- PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
- Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
- Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.
- Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.

10h45-11h45— SIMPÓSIO

11h45-13h00 — SISTEMA NERVOSO CENTRAL

Moderadores: Andreia Costa, Marta Almeida

Palestrante: Filipa Carneiro

- INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
- Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses.
- Belzutifan treatment for von Hippel-Lindau (VHL) disease-associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study.
- Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study.